The company was taken private in 2007 for $11.3 billion by Blackstone Group, DDR & Co., TPG and Goldman Sachs Group, with each company contributing $1.3 billion and the rest covered with new debt, $5.9 billion of which is still on Biomet’s balance sheets.
Biomet selected Bank of America Merrill Lynch, Goldman Sachs Group and JPMorgan Chase to lead the IPO.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
